- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05303753
Protein-Prebiotic Wellbeing Study
An Exploratory Study on the Effect of Fermented Dairy Protein With Prebiotic Fiber in Athletes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A substantial number of athletes suffer from gastro-intestinal problems, which may impair performance and/or subsequent recovery. Also, gut barrier integrity is impaired with high-intensity training. Emerging studies are showing a positive correlation between the gut microbiome and muscle function, athletic performance, body composition, and natural energy levels. This study will perform an exploratory analysis of the well-being and digestive health of well-trained athletes, and assess the potential effect of fermented dairy protein with prebiotic fiber on these parameters.
Question 1: Does the 3-week supplementation of a fermented dairy protein with prebiotic fiber affect the self-reported digestive comfort compared to a 3-week baseline period? And additionally, will the quality of life (self-reported general well-being and states of mood) change with the use of this type of product?
Question 2: Does the 3-week supplementation of a fermented dairy protein with prebiotic fiber show an alteration in gut microbiota in comparison to a 3-week baseline period, while dietary intake remains unaffected?
Question 3: How is the 3-week supplementation of a fermented dairy protein with prebiotic fiber experienced by the participants (taste and concept liking)?
Question 4: Is there a difference in baseline gut microbiota between athletes with and athletes without self-reported GI complaints.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85004
- Arizona State University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy subjects living in Arizona in the USA
- Women/Men aged between 18-35 years
- Serious athletes (exercise at least 3 x per week)
- With or without GI tract issues due to sport or protein/diet intake
- 18.5 ≤ BMI ≤ 40 kg/m2
- No physical limitations (i.e. able to perform all activities associated with daily living in an independent manner).
- Use of a protein supplement or sports food after at least one training per day 3 x per week
- Willing to slightly increase their protein supplement intake during the intervention phase for 21 consecutive days
- Stable weight during the last 4 weeks, without a focus on body weight reduction through limiting caloric intake
- Written informed consent
Exclusion Criteria:
- Daily use of (sport) supplements containing probiotics and/or prebiotics
- Smoking
- Self-reported cow's milk protein allergy
- Clinical lactose intolerance
- Clinical milk protein allergy
- House dust mite allergy
- Diagnosed GI tract disorders or diseases
- Musculoskeletal disorders
- Metabolic disorders (such as diabetes)
- Use of any medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescribed acne medications).
- Chronic use of gastric acid-suppressing medication or anti-coagulants
- Use of antibiotics or anti-inflammatory medication the past 2 weeks
- Blood donation in the past 2 months
- Pregnant/lactating women
- Athletes should not aim to lose body weight by reducing energy intake during the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Single group
During a 3-week baseline period, participants with self-reported GI complaints consume their own protein supplement that they use for recovery purposes after exercise, followed by a 3-week intervention period in which they maintain usage of their own product, but replace a part of this product with a fermented dairy protein with prebiotic fiber.
An additional reference group of athletes without self-reported GI complaints will also be followed during a 3-week period in which they consume their own protein supplement that they use for recovery purposes after exercise.
|
During the intervention period, the participant will consume a new product and will reduce the amount of protein in their normal diet reflecting the protein content of the new product.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in self-reported digestive comfort
Time Frame: Baseline (day 0), after 21 days and after 42 days.
|
Gastrointestinal Symptoms Rating Scores (GSRS-score: Average of all 5 sub-scores)
|
Baseline (day 0), after 21 days and after 42 days.
|
|
Change in daily self-reported digestive comfort
Time Frame: Study period covering day 1 to day 21 compared to day 22-42.
|
Daily variation of GI complaints (averaged itemized score 1-10)
|
Study period covering day 1 to day 21 compared to day 22-42.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in self-reported general wellbeing - Physical Health
Time Frame: Baseline (day 0), after 21 days and after 42 days.
|
Reported as physical wellbeing (Physical Health Questionnaire, PHX - average score 1-7 based on 14 items)
|
Baseline (day 0), after 21 days and after 42 days.
|
|
Change in self-reported general wellbeing - Psychological Distress
Time Frame: Baseline (day 0), after 21 days and after 42 days.
|
Reported as psychological distress (mental distress, K6 scale - average score 0-24).
|
Baseline (day 0), after 21 days and after 42 days.
|
|
Change in participants microbiota composition of fecal samples
Time Frame: Baseline (day 0), after 21 days and after 42 days.
|
16s microbial profiling
|
Baseline (day 0), after 21 days and after 42 days.
|
|
Change in dietary intake
Time Frame: Baseline (day 0), after 21 days and after 42 days.
|
24-hour dietary recalls (food group intake, energy and macro- and micronutrient)
|
Baseline (day 0), after 21 days and after 42 days.
|
|
Chane in self-reported states of mood
Time Frame: Baseline (day 0), after 21 days and after 42 days.
|
Profile of Mood States (POMS)
|
Baseline (day 0), after 21 days and after 42 days.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in food composition and diet quality
Time Frame: Baseline (day 0), after 21 days and after 42 days.
|
Rapid eating assessment in participants (REAP)
|
Baseline (day 0), after 21 days and after 42 days.
|
|
Change in product experience
Time Frame: Baseline (day 0), days 22, 23, 29, 36, 43.
|
Question about product experience (taste and concept liking)
|
Baseline (day 0), days 22, 23, 29, 36, 43.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Floris Wardenaar, PhD, Arizona State University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- STUDY00014399
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Quality of Life
-
Ziekenhuis Oost-LimburgRecruitingQuality of Life | Postoperative Quality of Recovery | Health-Related Quality-of-LifeBelgium
-
Assiut UniversityUnknownImproving Quality of LifeEgypt
-
B. Braun Medical SAUnknownQuality of Life of Colostomized Patient
-
Istituto Ortopedico RizzoliUniversity of BolognaCompletedImprove Quality of LifeItaly
-
Children's National Research InstituteCompletedProfessional Quality of LifeUnited States
-
Mattu UniversityCompletedBreif Description: Patients' Quality of Life ofEthiopia
-
University of South CarolinaNational Institute on Minority Health and Health Disparities (NIMHD)RecruitingHealth Related Quality of LifeUnited States
-
PharmanexSprim Advanced Life SciencesCompletedHealth-related Quality of LifeUnited States
-
Region VästmanlandUnknownHealth Related Quality of Life
-
Ain Shams UniversityCompletedHealth Related Quality of LifeEgypt
Clinical Trials on fermented dairy protein with prebiotic fiber
-
Arizona State UniversityFriesland CampinaRecruitingQuality of Life | Digestive HealthUnited States
-
Hospital Clinico Universitario de SantiagoMinisterio de Economía y Competitividad, SpainCompleted
-
University of CalgaryGeneral MillsCompleted
-
Danone JapanCompleted
-
Danone JapanCompletedSubjects With High LDL-CholesterolJapan
-
University of ZagrebCroatian Science FoundationCompletedMicrobiota | Sports | Dietary Fiber | Nutrition Surveys | Sports NutritionCroatia
-
Danone JapanCompletedNormal and Mild Hypercholesterolemic SubjectsJapan
-
Faidon MagkosUniversity of Aarhus; Arla Food for Health; Mælkeafgiftsfonden; University of Copenhagen...CompletedMetabolic Syndrome | Overweight or ObesityDenmark
-
NIN InstituteCentro Medico IssemymActive, not recruitingDysbiosis Symptoms Linked to Pathology | Chronic Kidney Disease(CKD) | Probiotics SupplementMexico
-
Danone SpainCompletedHypercholesterolemiaSpain